Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog

Nature Structural Biology

Volumn 10, Issue 1, 2003, Pages 19-25

  Rasmussen, Hanne B ^a   Branner, Sven ^a   Wiberg, Finn C ^a,b   Wagtmann, Nicolai ^a  

^a NOVO NORDISK A S   (Denmark)

^b Symphogen AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROLASE; BETA HYDROLASE; DIPEPTIDYL PEPTIDASE IV; ENZYME INHIBITOR; HYDROLASE; UNCLASSIFIED DRUG; VALINE PYRROLIDIDE;

ALPHA HELIX; AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBUNIT; PRIORITY JOURNAL;

ANTIGENS, CD26; BINDING SITES; CATALYSIS; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; HUMANS; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; SUBSTRATE SPECIFICITY;

EID: 0037219684     PISSN: 10728368     EISSN: None     Source Type: Journal    
DOI: 10.1038/nsb882     Document Type: Article

References (35)

1. Mentlein, R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 85, 9-24 (1999).
2. Korom, S. et al. Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation 63, 1495-1500 (1997).
3. Tanaka, S. et al. Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int. J. Immunopharmacol. 19, 15-24 (1997).
4. Steinbrecher, A. et al. Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-β 1 secretion in vivo. J. Immunol. 166, 2041-2048 (2001).
5. De Meester, I., Korom, S., Van Damme, J. & Scharpe, S. CD26, let it cut or cut it down. Immunol. Today 20, 367-375 (1999).
6. Marguet, D. et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. USA 97, 6874-6879 (2000).
7. Deacon, C.F., Hughes, T.E. & Hoist, J.J. Dipeptidyl-peptidase-iv inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in the anesthetized pig. Diabetes 47, 764-769 (1998).
8. Pederson, R.A. et at. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide-1 receptor(-/-)-mice. Diabetes 47, 1046-1052 (1998).
9. Pauly, R.P. et at. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor ile-thiazolidide. Metab. Clin. Exp. 48, 385-389 (1999).
10. Balkan, B., Kwasnik, L., Miserendino, R., Hoist, J.J. & Li, X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1(7-36 amide) concentrations and improves oral glucose tolreance in obese Zucker rats. Diabetology 42, 1324-1331 (1999).
11. Ahren, B. et at. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25, 869-875 (2002).
12. Kameoka, J., Tanaka, T., Nojima, Y., Schlossman, S.F. & Morimoto, C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 261, 466-469 (1993).
13. + exchanger isoform NH E3 and dipeptidyl peptidase IV in the renal proximal tubule. J. Biol. Chem. 276, 46671-46677 (2001).
14. Ishii, T. et al. CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. Proc. Natl. Acad. Sci. USA 98, 12138-12143 (2001).
15. Morimoto, C. & Schlossman, S.F. The structure and function of cd26 in the T-cell immune-response. Immunol. Rev. 161, 55-70 (1998).
16. Wesley, U.V., Albino, A.P., Tiwari, S. & Houghton, A.N. A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic. J. Exp. Med. 190, 311-322 (1999).
17. Marguet, D. et al. cDNA cloning for mouse thymocyte-activating molecule. A multifunctional ecto-dipeptidyl peptidase IV (CD26) included in a subgroup of serine proteases. J. Biol. Chem. 267, 2200-2208 (1992).
18. Gorrell, M.D., Gysbers, V. & McCaughan, G.W. CD26: A multifunctional integral membrane and secreted protein of activated lymphocytes. Scand. J. Immunol. 54, 249-264 (2001).
19. Fulop, V., Bocskei, Z. & Polgar, L. Prolyl oligopeptidase: An unusual β-propeller domain regulates proteolysis. Cell 94, 161-170 (1998).
20. Abbott, C.A.G. & Gorrell, M.D. The family of CD26/DPIV and related ectopeptidases, in Ectopeptidases: CD13/Aminopeptidase N and CD26/Dipeptidylpeptidase IV in Medicine and Biology (eds. Langner, J & Ansorge, S.) 171-184 (Kluwer/Plenum, New York; 2002).
21. Abbott, C.A., McCaughan, G.W., Levy, M.T., Church, W.B. & Gorrell, M.D. Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted β propeller domain. Eur. J. Biochern. 266, 798-810 (1999).
22. Smith, T.F., Gaitatzes, C., Saxena, K. & Neet, E.J. The WD repeat: A common architecture for diverse functions. Trends Biochern. Sci. 24, 181-185 (1999).
23. Fulop, V. & Jones, D.T. β-properlers: Structural rigidity and functional diversity. Curr. Opin. Struct. Biol. 9, 715-721 (1999).
24. Fulop, V., Szeltner, Z. & Polgar, L. Catalysis of serine oligopeptidases is controlled by a gating filter mechanism. EMBO Rep. 1, 277-281 (2000).
25. Abbott, C.A., McCaughan, G.W. & Gorrell, M.D. Two highly conserved glutamic acid residues in the predicted β propeller domain of dipeptidyl peptidase IV are required for its enzyme activity. FEBS Lett. 458, 278-284 (1999).
26. Reva, B., Finkelstein, A. & Topiol, S. Threading with chemostructural restrictions method for predicting fold and functionally significant residues: Application to dipeptidylpeptidase IV (DPP-IV). Proteins 47, 180-193 (2002).
27. Brandt, W. Development of a tertiary-structure model of the C-terminal domain of DPP IV. Adv. Exp. Med. Biol. 477, 97-101 (2000).
28. De Meester, I., Vanhoof, G., Lambeir, A.M. & Scharpe, S. Use of immobilized adenosine-deaminase (EC 3.5.4.4) for the rapid purification of native human CD26 dipeptidyl peptidase IV (EC 3.4, 14.5). J. Immunol. Methods 189, 99-105 (1996).
29. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
30. Collaborative Computational Project, Number 4. The CCP4 suite: Programs for protein crystallography. Acta Crystallogr D 50, 760-763 (1994).
31. Terwilliger, T.C. & Berendzen, J. Automated MAD and MIR structure solution. Acta Crystallogr. D 55, 849-861 (1999).
32. de La Fotelle, E. & Bricogne, G. Maximum-likelihood heavy-atom parameter refinement for multiple isomorphous replacement and multiwavelength anomalous diffraction methods. Methods Enzymol. 276, 472-494 (1997).
33. 1 ATPase. Acta Crystallogr. D 52, 30-42 (1996).
34. Brunger, A.T. et al. Crystallography & NMR System: A new software suite for macromolecular structure determination. Acta Crystallogr. D 54, 905-921 (1998).
35. Nicholls, A., Sharp, K.A. & Honig, B. Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 11, 281-296 (1991).